TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04946370: Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

Sponsor: Weill Medical College of Cornell University · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 52 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$6,754,440

Rescue Site Savings

+$4,476,780

Unlock Full NCT04946370 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04946370 Rescue Dossier →